Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma
OncologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- International journal of radiation oncology, biology, physics
- Publicado em
- 15 jan 2024
- Citações
- 19
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Prospective Randomized Phase 2 Trial of Hypofractionated Stereotactic Radiation Therapy of 25 Gy in 5 Fractions Compared With 35 Gy in 5 Fractions in the Reirradiation of Recurrent Glioblastoma
Andre Tsin Chih Chen, Alexandre Ruggieri Serante, Aline Sgnolf Ayres, Juliana Ono Tonaki, Raquel Andrade Moreno, Helen Shih, Gabriel Scarabotolo Gattás, Rossana Verónica Mendoza López, Gabriela Reis Dos Santos de Jesus, Icaro Thiago de Carvalho et al.
Descritores MeSH
- Brain Neoplasms
- Re-Irradiation
- Glioblastoma
- Neoplasm Recurrence, Local
- Progression-Free Survival
- Radiosurgery
- Radiation Dose Hypofractionation
- Necrosis
- Prospective Studies
- Dose Fractionation, Radiation
Veja também
Estudos relacionados
- Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma
- Hypofractionated Stereotactic Re-irradiation and Anti-PDL1 Durvalumab Combination in Recurrent Glioblastoma: STERIMGLI Phase I Results
- Restrições de dose de radiação de risco: atualização de 2025
- Magnetic resonance spectroscopy (MRS) for differentiating tumour recurrence from radiation necrosis in treated intra-axial brain tumours